Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Over the past decade, research advances, infrastructure and ecosystem improvements and drug regulatory system reforms have boosted the level of innovative drug research and development (R&D) in China. Furthermore, Chinese pharmaceutical companies have accelerated their integration into the global drug development enterprise by conducting clinical trials outside of China. Since February 2007, when the Chinese company Tasly Pharmaceuticals announced its decision to conduct a phase II trial in the USA for dantonic (T89), the first Chinese innovative drug to undergo clinical trials in the United States, the number of drugs of Chinese origin tested in the USA has grown steadily.